Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 28, 2024; 30(44): 4763-4767
Published online Nov 28, 2024. doi: 10.3748/wjg.v30.i44.4763
Published online Nov 28, 2024. doi: 10.3748/wjg.v30.i44.4763
Unveiling the intricacies of irritable bowel syndrome
Duygu Kirkik, Sevgi Kalkanli Tas, Department of Immunology, University of Health Sciences, Hamidiye Medicine Faculty, Istanbul 34668, Türkiye
Duygu Kirkik, Department of Medical Biology, University of Health Sciences, Hamidiye Medicine Faculty, Istanbul 34668, Türkiye
Co-first authors: Duygu Kirkik and Sevgi Kalkanli Tas.
Author contributions: Kirkik D and Kalkanli Tas S wrote the original draft, prepared the figure, and revised the manuscript.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Duygu Kirkik, BSc, MSc, PhD, Assistant Professor, Department of Immunology, University of Health Sciences, Hamidiye Medicine Faculty, Mekteb-i Tıbbiyye-i Şâhane (Haydarpaşa) Külliyesi Selimiye Mah. Tıbbiye Cad. No:38 34668 Üsküdar, Istanbul 34668, Türkiye. dygkirkik@gmail.com
Received: September 12, 2024
Revised: September 26, 2024
Accepted: October 18, 2024
Published online: November 28, 2024
Processing time: 60 Days and 11.6 Hours
Revised: September 26, 2024
Accepted: October 18, 2024
Published online: November 28, 2024
Processing time: 60 Days and 11.6 Hours
Core Tip
Core Tip: This letter provides a comprehensive review of the interaction between the neuroendocrine axis, gut microbiota, and inflammation plays a pivotal role in the development of irritable bowel syndrome (IBS). This study reveals that imbalances in these systems, such as elevated stress hormones and altered microbial populations, exacerbate IBS symptoms. Targeted therapeutic approaches that modulate these interconnected pathways may offer new hope for personalized treatment options.